Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy
| Autor: | Richard Fischer, Matthias Breidert, Tobias Keck, Frank Makowiec, Christian Lohrmann, Jan Harder |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: | |
| Zdroj: | The Saudi Journal of Gastroenterology, Vol 18, Iss 2, Pp 118-121 (2012) |
| Druh dokumentu: | article |
| ISSN: | 1319-3767 1998-4049 |
| DOI: | 10.4103/1319-3767.93815 |
| Popis: | Background/Aim: Adjuvant chemotherapy for 6 months is the current standard of care after potentially curative resection of pancreatic cancer and yields an overall survival of 15-20 months. Early tumor recurrence before or during adjuvant chemotherapy has not been evaluated so far. These patients may not benefit from adjuvant treatment. Patients and Methods: Thirty-five patients with resection of ductal pancreatic carcinoma and adjuvant chemotherapy with gemcitabine were analyzed between 2005 and 2007. All patients had a computed tomography (CT) scan before and during adjuvant chemotherapy after 2-3 months, 12/35 patients had a histologically confirmed R1 resection. Recurrence of pancreatic cancer was determined by CT scan and the clinical course. Results: Median survival of 35 patients with resected pancreatic cancer was 19.7 months, and the 2-year survival was 44%. Thirteen (37%) of the 35 patients analyzed with a CT scan showed tumor recurrence during adjuvant chemotherapy. Overall survival of patients with tumor recurrence was 9.3 months with a 2-year survival rate of 13%, whereas median overall survival of patients without early relapse was 26.3 months (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|